Background: Readily available testing for SARS-CoV-2 is necessary to mitigate COVID-19 disease outbreaks. At-home collection kits, in which samples are self-collected without requiring a laboratory or clinic visit and sent to an external laboratory for testing, can provide convenient testing to those with barriers to access. They can prevent unnecessary exposure between patient and clinical staff, increase access for patients with disabilities or remote workers, and decrease burdens on health care resources, such as provider time and personal protective equipment. Exact Sciences developed an at-home collection kit for samples to be tested to detect SARS-CoV-2 that includes an Instructions for Use (IFU) document, which guides people without prior experience on collecting a nasal swab sample. Demonstrating successful sample collection and usability is critical to ensure that these samples meet the same high-quality sample collection standards as samples collected in clinics.
Objective: The aim of this study was to determine the usability of a SARS-CoV-2 at-home nasal swab sample collection kit.
Methods: A human factors usability study was conducted with 30 subjects without prior medical, laboratory, or health care training and without COVID-19 sample self-collection experience. Subjects were observed while they followed the IFU for the at-home sample collection portion of the SARS-CoV-2 test in a setting that simulated a home environment. IFU usability was further evaluated by requiring the subjects to complete a survey, answer comprehension questions, provide written feedback, and respond to questions from the observer about problems during use.
Results: All 30 subjects successfully completed the sample collection process, and all 30 samples were determined by reverse transcription–polymerase chain reaction (RT-PCR) testing to meet quality standards for SARS-CoV-2 testing. The subjects’ written feedback and comments revealed several recommendations to improve the IFU.
Conclusions: The study demonstrated the overall usability of an at-home SARS-CoV-2 collection kit. Various feedback mechanisms provided opportunities to improve the wording and graphics for some critical tasks, including placing the label correctly on the tube. A modified IFU was prepared based on study outcomes.
The global pandemic caused by SARS-CoV-2 has resulted in 223 million confirmed cases of COVID-19, including 4.6 million deaths, as of September 2021, according to the World Health Organization . In the United States, there have been more than 40.3 million reported COVID-19 cases and more than 649,000 deaths as of September 2021 [ ]. The transmission of COVID-19 has been shown to be contained with a combination of isolation practices, including wearing masks, physical distancing, and lockdown measures [ ], and widespread immunization with effective COVID-19 vaccines [ ]. In the United States, more than 175 million people have been fully vaccinated as of September 2021 using one of three COVID-19 vaccines [ - ] currently authorized for emergency use by the US Food and Drug Administration (FDA)—in August 2021, the FDA approved Comirnaty, known previously as the Pfizer-BioNTech COVID-19 vaccine, for individuals 16 years of age or older [ ].
Despite this monumental progress, significant challenges remain to manage the ongoing pandemic. Many eligible Americans have not been vaccinated , and the emergence of increasingly virulent strains, including the Delta variant [ ], have resulted in increased hospitalizations and deaths throughout the United States [ , ]. Widespread testing can help public health officials to better monitor the progression of the pandemic, identify emerging variants, and identify individuals with COVID-19, particularly those with asymptomatic disease.
One approach to broadening access to SARS-CoV-2 testing has been the development of at-home sample collection kits that could be used safely and effectively by people without medical or laboratory experience. Samples can be collected without needing to travel to a medical center, and the samples can be shipped and later processed at a laboratory or health care facility or tested at home . At-home sample collection offers multiple advantages to combat the COVID-19 pandemic: it can prevent unnecessary exposure between patients and clinical staff during collection; improve access for elderly patients, patients with disabilities, or remote workers; reduce the need for personal protective equipment; and shift the logistics of collection from overburdened clinical sites to commercial delivery services.
Surveys on the perception of at-home COVID-19 sample collection and tests have demonstrated a broad willingness to complete such collection and confidence in the sample preparation and quality . Multiple studies have been conducted recently to compare SARS-CoV-2 test results from self-collected samples to those collected by health care workers [ - ]. Recently, a large-scale population-based study on the applicability of COVID-19 self-testing demonstrated that most participants collected the sample correctly the first time, and that test results showed comparable performance to those collected by health care professionals [ ].
To investigate the usability of an at-home collection process, usability studies should be conducted to ensure that these samples meet the same quality standards as clinician-collected samples. Here, we describe the results of a human factors usability study, conducted early in the pandemic, for the at-home sample collection kit, herein referred to as the “SARS-CoV-2 at-home collection kit,” for use with the SARS-CoV-2 (N gene detection) Test, both of which were developed by Exact Sciences. Exact Sciences is a molecular diagnostics company that manufactures an at-home screening test for colorectal cancer and developed the SARS-CoV-2 at-home collection kit and test in response to the global pandemic. Additional details related to the SARS-CoV-2 test are available in the FDA’s Emergency Use Authorization (EUA) documentation in.
The goal of this study was to determine the usability of the SARS-CoV-2 at-home collection kit, and our primary endpoint was the percentage of samples collected from study participants that returned a valid SARS-CoV-2 result.
This study was conducted in May 2020, during the early months of the pandemic when very little information about COVID-19 pathogenesis was available, and the protocol was designed based on standards for human factors usability study design . By publishing our methodology and outcomes, we hope to provide a blueprint for future studies to ensure that the usability of other at-home collection kits can be quickly evaluated during public health crises or similar situations where urgency is required.
The SARS-CoV-2 (N gene detection) Test was developed by Exact Sciences and received EUA from the FDA on May 22, 2020, via EUA200367 (). A summary of the SARS-CoV-2 test characteristics is provided in . This is a reverse transcription–polymerase chain reaction (RT-PCR)–based test that evaluates upper respiratory samples, including those collected with an anterior nares (ie, nasal) swab, to detect regions within the nucleocapsid (N) gene of the novel coronavirus (nCoV), specifically the nCoV_N1 and nCoV_N2 regions. Human ribonuclease P (RNase P), a gene expressed ubiquitously in human cells regardless of COVID-19 infection, serves as a control to demonstrate that usable samples were collected and provided to the lab, and that all testing processes were successfully completed. In validation studies, the test demonstrated no cross-reactivity with a panel of known respiratory pathogens. Its preclinical test performance in a collection of test samples showed positive percent agreement of 95% (38 out of 40 samples) and negative percent agreement of 100% (38 out of 38 samples) with another FDA-authorized SARS-CoV-2 RT-PCR-based test.
The SARS-CoV-2 at-home collection kit contains the following: a sterile, individually wrapped nasal swab with a polyester tip with plastic handle; a 2-mL transport tube containing 0.9% saline; an Instructions for Use (IFU) document; a biohazard bag; an absorbent pad; a specimen identification label; and a UN3373-labeled shipping container.
|Test name||SARS-CoV-2 (N gene detection) Test|
|Type of test||Real-time RT-PCRb|
|Gene regions detected|
|SARS-CoV-2||nCoVc_N1 and nCoV_N2 regions of the nucleocapsid (N) gene|
|Control||Ribonuclease P human gene locus|
|Limit of detection||2.6 genome copies/µL sample|
|Cross-reactivity||13 other respiratory pathogens not detectedd|
|Preclinical test performancee (n=78 samples)|
|Positive percent agreement (38 out of 40 samples), % (95% CI)||95.0 (83.5-98.6)|
|Negative percent agreement (38 out of 38 samples), % (95% CI)||100 (90.8-100)|
aTest details were obtained from the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) summary ().
bRT-PCR: reverse transcription–polymerase chain reaction.
cnCoV: novel coronavirus.
dThe detection assay was conducted using NATtrol Respiratory Pathogen Panel-1 (NATRPP-1) from Zeptometrix.
eIn comparison with another COVID-19 RT-PCR test with FDA EUA.
Study Objectives and Subjects
The main objective was to determine the usability of the SARS-CoV-2 at-home collection kit for the collection and mailing of a nasal swab sample to the testing laboratory. The primary endpoint was the percentage of samples from the study participants that returned a valid SARS-CoV-2 test result, either positive or negative, both of which require a detectable level of RNase P. The target percentage was 80%, given that the subjects were minimally trained and were inexperienced in sample self-collection. There were five secondary objectives: (1) evaluate the perceived usability of the IFU, (2) evaluate the comprehension of the IFU by the subject, (3) identify problems that occur while following the IFU, (4) evaluate the root causes of problems that occur while following the IFU, and (5) develop strategies to mitigate problems occurring while following the IFU. A total of 30 patients from a workforce population that met established inclusion and exclusion criteria were enrolled in this study. Steps were taken to recruit subjects of varying ages and educational statuses, which included a manual review of participants by the study team.
The study was conducted in accordance with state and federal regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects  and the Declaration of Helsinki [ ]. The study was approved by the Western Institutional Review Board (WIRB)–Copernicus Group Institutional Review Board (No. 20201763) and all subjects provided written informed consent prior to study participation.
The inclusion criterion was the ability to provide informed consent, and the exclusion criteria were prior medical or laboratory training, prior experience with COVID-19 sample self-collection, and prior SARS-CoV-2 testing. For each enrolled subject, usability of the IFU was determined based on successful completion of the self-collection of a nasal swab sample, which included a valid SARS-CoV-2 test result. All subjects completed the study.
A use-related Failure Mode Effects Analysis approach was used to determine potential hazards and their associated risks during use of the SARS-CoV-2 at-home collection kit. Subjects completed a survey form with demographic information, including race and ethnicity , highest education level obtained, and prior experience with medical or laboratory training and COVID-19 sample self-collection. Subjects who provided informed consent were provided an overview of the clinical study procedures, including guidance that they would be observed during the sample collection and answer questions related to their experience during the sample collection. The study consisted of two parts: simulated use, in which sample collection was simulated by a subject while monitored by an observer; and postsimulation evaluation, in which the subject completed survey questions and provided feedback on the collection process. The overall study design and methodology is summarized in .
The sample collection took place in a simulated home environment in a conference room with a table that served as a large surface area, similar to a countertop found in a kitchen or bathroom. The room included common household items, such as hand sanitizer, pens, pencils, paper towels, and a wastebasket. Since a sink was not available in the room, a large bowl labelled “SINK” was provided next to the hand sanitizer to simulate a sink for handwashing with soap and water.
Before beginning the sample collection, the observer oriented the subject to the simulated environment, making them aware of items available to them, without indicating that these would be required for the sample collection to reduce bias to the subject. To begin the sample collection, the observer instructed the subject to retrieve an available kit and to begin the collection; subjects were then observed while following the IFU for the SARS-CoV-2 at-home collection kit. The identification and classification of tasks were made by the study researchers (seefor complete list of tasks), and the study participants were blinded to the task categories.
Following completion of all steps in the IFU, the subject was then instructed to place the sample package in a designated area within the conference room. The subject then provided feedback on the usability of the IFU by completing the After-Scenario Questionnaire (ASQ) [- ], answered comprehension questions, provided written feedback on the experience, and addressed questions from the observer about observed problems during use.
The samples collected by the subjects were tested for SARS-CoV-2 by Exact Sciences Laboratories. Subjects remained blinded to the test results.
The study was conducted using the SARS-CoV-2 at-home collection kit from Exact Sciences; test characteristics are summarized in( ). Briefly, the laboratory test used RT-PCR to detect SARS-CoV-2 from a sample collected using an anterior nares (ie, nasal) swab, using detection of human RNase P as a control.
For the human factors usability study, 30 subjects were enrolled to simulate at-home sample collection and provide feedback during the follow-up evaluation (). The characteristics of the study subjects (N=30) are described in . The mean age of the subjects was 38.0 (SD 9.7) years, and no subjects were older than 65 years. Most subjects were White (n=26, 87%) and non-Hispanic or non-Latino (n=25, 83%), and 77% (n=23) of subjects had more than a high school education. After completing the usability study, all 30 subjects’ self-collected samples resulted in a valid SARS-CoV-2 test result, and all were negative for SARS-CoV-2. Sample validity was determined by successful detection of human RNase P.
Subjects completed the simulated sample collection according to an IFU document that described the 26 tasks required to prepare, collect, and ship a nasal swab sample (seefor complete list of tasks). These tasks were divided into “critical tasks,” in which use errors or failure to complete would have a negative clinical impact, such as invalid or delayed test results, and “essential tasks,” which were important for test completion but did not pose an immediate risk to the sample. Out of the 26 tasks, 15 were categorized as “critical” and were the primary focus for evaluating and improving the IFU based on study outcomes and subject feedback.
Overall, 14 out of 15 critical tasks from the IFU were successfully completed by more than 80% of the subjects during the simulated sample collection (). The task that the subjects encountered the greatest difficulty with was placing the label on the tube, which was not completed properly by 70% (21/30) of the subjects.
|Age (years), mean (SD)||38.0 (9.7)|
|Age category (years), n (%)|
|Sex, n (%)|
|Ethnicity, n (%)|
|Hispanic or Latino||4 (13)|
|Non-Hispanic or non-Latino||25 (83)|
|Racea, n (%)|
|American Indian or Alaska Native||0 (0)|
|Black or African American||2 (7)|
|Native Hawaiian or other Pacific Islander||0 (0)|
|Education level, n (%)|
|No high school||0 (0)|
|Some high school||0 (0)|
|High school degree only||7 (23)|
|College degree||18 (60)|
|Advanced degree||5 (17)|
aSubjects had the option to report one or more categories for race; each participant selected an option for both ethnicity and race.
To evaluate the opinions of the subjects after the simulated sample collection, subjects completed the ASQ () [ ]. Responses were indicated on a scale of 1 to 7, with lower scores corresponding to higher satisfaction; scores of less than 3 indicated that subjects felt satisfied using the IFU for sample collection. For all questions among the 30 subjects, the mean overall ASQ score was 2.1 (SD 1.6), indicating overall satisfaction.
The subjects’ written feedback and comments to the observer revealed several areas of potential improvement to the IFU. Most comments focused on references to the front and back of the IFU, handwashing, handling the absorbent pad, how far into the nostrils the nasal swab should be inserted (eg, use of the word “resistance”), and issues related to the tube label (eg, writing on the label and attaching it to the tube).
Results from the multiple sources of feedback collected during the feasibility study () were combined to determine how to improve the usability of the IFU (see for complete list of changes and corresponding rationale). This feedback helped improve the language and graphics describing how to place the label on the tube, which is the critical task with the lowest successful completion rate. Furthermore, subjects suggested minor wording changes to improve comprehension (eg, replacing “discard swab into your waste” with “throw swab into the trash”). The updated IFU is shown in .
|Feedback||Categories or questions||Measurement|
|Observer evaluation of IFU||The observer selected one of four options:|
|ASQ questions||The subject recorded their response on a numerical 7-point scale, ranging from 1 (“strongly agree”) to 7 (“strongly disagree”), and “N/A” (not applicable) outside the scale.|
|IFU comprehension||The observer recorded the response as “correct” or “incorrect” (with the option to record free-form text and ask follow-up questions).|
|Written feedback||The observer recorded the response as free-form text (with the option to ask follow-up questions).|
|Observer questions||The observer recorded the response as “yes” or “no.”|
Overall, this simulated at-home self-collection usability study was successful in that all 30 subjects collected samples that resulted in valid test results (100% success rate, exceeding the targeted 80%). Moreover, the ASQ scores were low, indicating acceptable agreement and satisfaction, and the written feedback and comments from subjects were combined with simulation data to improve the IFU for future patients undergoing COVID-19 testing using at-home specimen collection.
To evaluate sample quality, the presence of human RNase P, a gene expressed ubiquitously in human cells regardless of COVID-19 infection, provided a universal measurement of quality control. If the sample contained a detectable level of RNase P, then it was determined that the sample had sufficient RNA to be tested for the presence of SARS-CoV-2. Notably, this standard can be used for any sample obtained using the at-home SARS-CoV-2 collection kit, regardless of the method of collection or the positive or negative outcome of the test. The preclinical test characteristics of the SARS-CoV-2 test, summarized in, demonstrated high positive and negative percent agreement among samples of sufficient quality.
The study population was well distributed with respect to age and gender. The proportion with a college degree or higher (77%) was slightly higher than the local population in Madison, Wisconsin (58%), although race and ethnicity populations were similar (ie, the White, non-Hispanic or non-Latino population in Madison is 74%) . Importantly, the qualifications for study participants impacted the inclusion criteria, which required the exclusion of anyone with any scientific or laboratory experience.
In general, the ability to provide at-home sample collection to detect respiratory viruses could significantly improve the effectiveness of public health strategies in preventing the spread of disease during a pandemic. For the COVID-19 pandemic, at-home sample collection could (1) improve the ability to identify individuals with detectable SARS-CoV-2 RNA without the need to expose health care workers during testing or the public during travel to and from the testing site, (2) provide an alternative and likely more accessible testing workflow for patients, and (3) enable the epidemiological study of the natural history of disease without undue risk to the population.
This study had several limitations. Some limitations were the simulated nature of the home environment, the lack of access to shipment methods for subjects, and the lack of subjects over 65 years, which was a result of the workforce population recruited for the study. Other limitations, including the relatively small sample size, were based on limited access of materials and a prioritization to make this collection kit available as soon as possible due to the ongoing public health crisis. Changes driven by logistics or product considerations and typographical errors are included in the updated IFU but are beyond the scope of this publication. The strengths of this study were that all subjects were able to successfully follow the IFU to collect usable samples, the consistency of the completion of medium-risk tasks, and the constructive feedback on low-risk tasks that led to IFU improvements.
In conclusion, this study demonstrated the overall usability of the SARS-CoV-2 at-home collection kit, and feedback from the study was used to generate improved instructions for use. Overall, it provides additional information that at-home collection of specimens for use with COVID-19 tests can be conducted effectively by subjects without prior sample self-collection experience.
We would like to thank the following contributors, who were all at Exact Sciences during the study design and execution: Steve Shak, MD, for scientific advice; Erin Bork, MS, Hannah McCracken, Marina Pavlova, Corey Yackel, Sarah Dunlap, PhD, and Claire Anderson for data processing assistance; Kourtney Frick for graphic design support; Rob Fisher, PhD, for Instructions for Use design and feedback incorporation; and everyone at Exact Sciences whose efforts and assistance helped make this study successful. This study was funded by Exact Sciences Corporation.
LES, MT, and KCA were responsible for conceptualization of the study. LES, IM, MT, and KCA were responsible for the study methodology. VS was responsible for software programming and data analysis. LES, MT, and VS were responsible for the formal analysis. IM was responsible for conducting the investigation and for project administration. DKEV was responsible for writing the original draft of the manuscript and for visualization of the results. LES, IM, MT, VS, DKEV, JM, and KCA were responsible for writing, reviewing, and editing the manuscript. LES, IM, and MT were responsible for project supervision.
Conflicts of Interest
MT, VS, DKEV, JM, and KCA are employees of Exact Sciences Corporation. LES and IM were employees of Exact Sciences Corporation when this study was conducted.
US Food and Drug Administration Emergency Use Authorization documentation for the Exact Sciences SARS-CoV-2 test.PDF File (Adobe PDF File), 444 KB
List of steps in Instructions for Use for the SARS-CoV-2 at-home collection kit. Critical steps are indicated in bold, which were not uniquely highlighted or bolded to subjects during the study.PDF File (Adobe PDF File), 466 KB
Final Instructions for Use document.PDF File (Adobe PDF File), 1069 KB
- WHO Coronavirus (COVID-19) Dashboard. World Health Organization. 2021. URL: https://covid19.who.int/ [accessed 2021-09-02]
- Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, COVID-19 Systematic Urgent Review Group Effort (SURGE). Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet 2020 Jun 27;395(10242):1973-1987 [FREE Full text] [CrossRef] [Medline]
- Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021 Feb;21(2):e26-e35 [FREE Full text] [CrossRef] [Medline]
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020 Dec 31;383(27):2603-2615 [FREE Full text] [CrossRef] [Medline]
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021 Feb 04;384(5):403-416 [FREE Full text] [CrossRef] [Medline]
- Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021 Jun 10;384(23):2187-2201 [FREE Full text] [CrossRef] [Medline]
- FDA approves first COVID-19 vaccine: Approval signifies key achievement for public health. US Food and Drug Administration. 2021 Aug 23. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine [accessed 2021-09-01]
- Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines (Basel) 2021 Mar 11;9(3):243 [FREE Full text] [CrossRef] [Medline]
- COVID Data Tracker. Centers for Disease Control and Prevention. URL: https://covid.cdc.gov/covid-data-tracker/#datatracker-home [accessed 2021-09-02]
- Griffin JB, Haddix M, Danza P, Fisher R, Koo TH, Traub E, et al. SARS-CoV-2 infections and hospitalizations among persons aged ≥16 years, by vaccination status- Los Angeles County, California, May 1-July 25, 2021. MMWR Morb Mortal Wkly Rep 2021 Aug 27;70(34):1170-1176 [FREE Full text] [CrossRef] [Medline]
- Fisher CE, Boeckh M, Jerome KR, Englund J, Kuypers J. Evaluating addition of self-collected throat swabs to nasal swabs for respiratory virus detection. J Clin Virol 2019 Jun;115:43-46 [FREE Full text] [CrossRef] [Medline]
- Valentine-Graves M, Hall E, Guest JL, Adam E, Valencia R, Shinn K, et al. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection acceptability of specimen collection process and patient confidence in specimens. PLoS One 2020;15(8):e0236775 [FREE Full text] [CrossRef] [Medline]
- Tu Y, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, et al. Swabs collected by patients or health care workers for SARS-CoV-2 testing. N Engl J Med 2020 Jul 30;383(5):494-496 [FREE Full text] [CrossRef] [Medline]
- Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, et al. Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic. J Clin Virol 2020 Jul;128:104417 [FREE Full text] [CrossRef] [Medline]
- Altamirano J, Govindarajan P, Blomkalns AL, Kushner LE, Stevens BA, Pinsky BA, et al. Assessment of sensitivity and specificity of patient-collected lower nasal specimens for severe acute respiratory syndrome coronavirus 2 testing. JAMA Netw Open 2020 Jun 01;3(6):e2012005 [FREE Full text] [CrossRef] [Medline]
- McCulloch DJ, Kim AE, Wilcox NC, Logue JK, Greninger AL, Englund JA, et al. Comparison of unsupervised home self-collected midnasal swabs with clinician-collected nasopharyngeal swabs for detection of SARS-CoV-2 infection. JAMA Netw Open 2020 Jul 01;3(7):e2016382 [FREE Full text] [CrossRef] [Medline]
- Therchilsen JH, von Buchwald C, Koch A, Dam Nielsen S, Rasmussen DB, Thudium RF, et al. Self-collected versus healthcare worker-collected swabs in the diagnosis of severe acute respiratory syndrome coronavirus 2. Diagnostics (Basel) 2020 Sep 09;10(9):678 [FREE Full text] [CrossRef] [Medline]
- Tan SY, Tey HL, Lim ETH, Toh ST, Chan YH, Tan PT, et al. The accuracy of healthcare worker versus self collected (2-in-1) oropharyngeal and bilateral mid-turbinate (OPMT) swabs and saliva samples for SARS-CoV-2. PLoS One 2020;15(12):e0244417 [FREE Full text] [CrossRef] [Medline]
- Iruzubieta P, Fernández-Lanas T, Rasines L, Cayon L, Álvarez-Cancelo A, Santos-Laso A, et al. Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. Sci Rep 2021 May 10;11(1):9819 [FREE Full text] [CrossRef] [Medline]
- Applying human factors and usability engineering to medical devices: Guidance for industry and Food and Drug Administration staff. US Food and Drug Administration. 2016 Feb. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices [accessed 2021-09-02]
- Council for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. Bull Med Ethics 2002 Oct(182):17-23. [Medline]
- World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013 Nov 27;310(20):2191-2194. [CrossRef] [Medline]
- Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies: Guidance for industry and Food and Drug Administration staff. US Food and Drug Administration. 2017 Sep. URL: https://tinyurl.com/bm7uhd3a [accessed 2021-09-02]
- Lewis JR. IBM computer usability satisfaction questionnaires: Psychometric evaluation and instructions for use. Int J Hum Comput Interact 1995 Jan;7(1):57-78. [CrossRef]
- Interim US guidance for risk assessment and work restrictions for healthcare personnel with potential exposure to COVID-19. Centers for Disease Control and Prevention. 2020 Oct 21. URL: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html [accessed 2021-09-02]
- Lewis JR. Psychometric evaluation of an after-scenario questionnaire for computer usability studies. SIGCHI Bull 1991 Jan 01;23(1):78-81. [CrossRef]
- QuickFacts: Madison city, Wisconsin. US Census Bureau. 2019. URL: https://www.census.gov/quickfacts/fact/table/madisoncitywisconsin# [accessed 2021-09-01]
|ASQ: After-Scenario Questionnaire|
|EUA: Emergency Use Authorization|
|FDA: Food and Drug Administration|
|IFU: Instructions for Use|
|nCoV: novel coronavirus|
|RNase P: ribonuclease P|
|RT-PCR: reverse transcription–polymerase chain reaction|
|WIRB: Western Institutional Review Board|
Edited by A Kushniruk; submitted 02.04.21; peer-reviewed by M Popovic, S Lalmuanawma; comments to author 25.08.21; revised version received 13.09.21; accepted 02.10.21; published 14.12.21Copyright
©Laura E Strong, Irene Middendorf, Michelle Turner, David K Edwards V, Varun Sama, Joshua Mou, K Colleen Adams. Originally published in JMIR Human Factors (https://humanfactors.jmir.org), 14.12.2021.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Human Factors, is properly cited. The complete bibliographic information, a link to the original publication on https://humanfactors.jmir.org, as well as this copyright and license information must be included.